Evidence for the production of three massive vector bosons with the ATLAS detector

A search for the production of three massive vector bosons in proton-proton collisions is performed using data at $\sqrt{s} = 13$ TeV recorded with the ATLAS detector at the Large Hadron Collider in the years 2015-2017, corresponding to an integrated luminosity of $79.8$ fb$^{-1}$. Events with two same-sign leptons $\ell$ (electrons or muons) and at least two reconstructed jets are selected to search for $WWW \to \ell \nu \ell \nu qq$. Events with three leptons without any same-flavour opposite-sign lepton pairs are used to search for $WWW \to \ell \nu \ell\nu \ell \nu$, while events with three leptons and at least one same-flavour opposite-sign lepton pair and one or more reconstructed jets are used to search for $WWZ \to \ell \nu qq \ell \ell$. Finally, events with four leptons are analysed to search for $WWZ \to \ell \nu \ell \nu \ell \ell$ and $WZZ \to qq \ell \ell \ell \ell$. Evidence for the joint production of three massive vector bosons is observed with a significance of 4.1 standard deviations, where the expectation is 3.1 standard deviations.Comment: 38 pages in total, author list starting page 22, 6 figures, 5 tables, matching published paper in Phys. Lett. B. All figures including auxiliary figures are available at http://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-2

Desempenho operacional de conjunto trator-recolhedora de feijão Evaluating the operational performance of a tractor-harvester system for beans

Estudos sobre a otimização do processo de colheita de grãos, dentre os quais, os de feijão, têm sido realizados pelo desenvolvimento e aperfeiçoamento de máquinas agrícolas, com a finalidade de aumentar o desempenho operacional, tornando-as mais eficientes e seguras, bem como aumentar a qualidade dos grãos colhidos. A avaliação do desempenho operacional de uma máquina viabiliza o seu emprego de forma técnica e economicamente organizada. Diante disso, este trabalho foi desenvolvido com o objetivo de avaliar o desempenho operacional de um conjunto trator-recolhedora de feijão. Foi utilizado um sistema de aquisição automática de dados, o que permitiu a coleta de dados, em tempo real, incluindo torque requerido e rotação da tomada de potência (TDP), e velocidade de deslocamento da recolhedora de feijão. Foram determinadas, também, a capacidade de processamento da máquina e as perdas ocorridas na área. O maior valor de torque requerido na TDP observado, durante ensaios de campo para a rotação de 7 Hz na TDP, foi de 731 Nm, enquanto, para a condição de 9 Hz, foi de 907 Nm. O conjunto apresentou, durante os ensaios de campo, capacidade média de processamento de 0,85 kg s-1, para área com produtividade média de 0,22 kg m-2. O produto foi colhido com umidade média de 13,6% b.u. em área de plantio direto e, nessas condições, o valor de perda encontrado totalizou 11,15%.<br>The beans harvesting system has been optimized by improving the mechanisms and the machines used. The objectives of the optimization works have been studied to increase the performance, efficiency and safety of the machines and to get better product quality. The objective of this work was to evaluate the operational performance of a tractor-harvester system for beans. The work was done using an automatic data acquisition system to acquire the torque and rotational velocity of the power take-off (PTO) and the system velocity. The processing capacity and the loss values were determined. The largest torque requirement, at 7 Hz PTO conditions, was 731 Nm, and the largest torque requirement, at the 9 Hz PTO conditions, was 907 Nm. The tractor-harvester system for beans showed, during field tests, a mean processing capacity of 0.85 kg s-1 for a production field condition of 0.22 kg m-2. The product was harvested at 13.6% moisture basis at a no-till area. At these conditions, it was found a total loss of 11.15%

Update of the Mexican college of rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis [Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología]

Background: The pharmacologic management of rheumatoid arthritis has progressed substantially over the past years. It is therefore desirable that existing information be periodically updated. There are several published international guidelines for the treatment of rheumatoid arthritis that hardly adapt to the Mexican health system because of its limited healthcare resources. Hence, it is imperative to unify the existing recommendations and to incorporate them to a set of clinical, updated recommendations; the Mexican College of Rheumatology developed these recommendations in order to offer an integral management approach of rheumatoid arthritis according to the resources of the Mexican health system. Objective: To review, update and improve the available evidence within clinical practice guidelines on the pharmacological management of rheumatoid arthritis and produce a set of recommendations adapted to the Mexican health system, according to evidence available through December 2012. Methods: The working group was composed of 30 trained and experienced rheumatologists with a high quality of clinical knowledge and judgment. Recommendations were based on the highest quality evidence from the previously established treatment guidelines, meta-analysis and controlled clinical trials for the adult population with rheumatoid arthritis. Results: During the conformation of this document, each working group settled the existing evidence from the different topics according to their experience. Finally, all the evidence and decisions were unified into a single document, treatment algorithm and drug standardization tables. Conclusions: This update of the Mexican Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis provides the highest quality information available at the time the working group undertook this review and contextualizes its use for the complex Mexican health system. © 2013 Elsevier España, S.L

Immunocompromised patients with acute respiratory distress syndrome : Secondary analysis of the LUNG SAFE database

The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge. Trial registration: ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013